newsfilter
← Latest News
Business Wire·

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

– Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented – Exelixis, Inc. (NASDAQ:EXEL) today announced presentations for its flagship product, CABOMETYX®